HBM Holdings (SEHK:2142) Wins Batoclimab Approval As Fair Value Stays In Focus

Simply Wall St.10-25

HBM Holdings (SEHK:2142) is in focus after China’s drug regulator approved batoclimab, a subcutaneous biologic for generalized myasthenia gravis, backed by a pivotal Phase 3 study showing clinically ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2678918099?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-25 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2678918099","market":"nz","top_or_hot":-1,"title":"HBM Holdings (SEHK:2142) Wins Batoclimab Approval As Fair Value Stays In Focus","media":"Simply Wall St.","content":"<div>\n<p>HBM Holdings (SEHK:2142) is in focus after China’s drug regulator approved batoclimab, a subcutaneous biologic for generalized myasthenia gravis, backed by a pivotal Phase 3 study showing clinically ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-wins-batoclimab-approval-as-fair-value\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings (SEHK:2142) Wins Batoclimab Approval As Fair Value Stays In Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings (SEHK:2142) Wins Batoclimab Approval As Fair Value Stays In Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-25 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-wins-batoclimab-approval-as-fair-value><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HBM Holdings (SEHK:2142) is in focus after China’s drug regulator approved batoclimab, a subcutaneous biologic for generalized myasthenia gravis, backed by a pivotal Phase 3 study showing clinically ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-wins-batoclimab-approval-as-fair-value\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MUG","symbol_name":"Leverage Shares 2X Long MU Daily ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-wins-batoclimab-approval-as-fair-value","article_id":"2678918099","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-wins-batoclimab-approval-as-fair-value","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2678918099","pubTimestamp":1792916664,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"HBM Holdings (SEHK:2142) is in focus after China’s drug regulator approved batoclimab, a subcutaneous biologic for generalized myasthenia gravis, backed by a pivotal Phase 3 study showing clinically meaningful patient improvements.\nHBM Holdings has had a choppy year in the market, with the 30-day share price return down 25.96% and the year-to-date share price return down 15.23%. However, the 3-year total shareholder return is very large at around 7x, so momentum has cooled recently even as...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MUG":"Leverage Shares 2X Long MU Daily ETF","BK1161":"生物科技","MUD":"1倍做空MU ETF-Direxion","MUU":"2倍做多MU ETF-Direxion","RAMZ":"T-REX 2X INVERSE DRAM DAILY TARGET ETF","COPP":"Sprott Copper Miners ETF","MIC":"2倍做多MU ETF-Corgi","BK1574":"生物医药B类股","MUYY":"GraniteShares YieldBOOSTMU ETF","BK1583":"高瓴概念","MULL":"2倍做多MU ETF-GraniteShares","MUZ":"2倍做空MU ETF-Defiance","DRMP":"Tuttle Capital Memory Stack Income Blast ETF","HBM":"HudBay Minerals Inc","DISK":"Tema Memory ETF","DRMY":"XFUNDS Memory Income ETF","BK4588":"碎股","DRAL":"2倍做多DRAM ETF-Defiance","DRAM":"Roundhill Memory ETF","02142":"和铂医药-B","HBMX":"Tuttle Capital Concentrated Memory Stack ETF","BK4168":"多种金属与采矿","RAM":"2倍做多DRAM ETF-T-REX"},"translate_title":"HBM Holdings (SEHK:2142) 赢得 Batoclimab 批准，公允价值仍然受到关注","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/e12575dd5e180c24a2b044d7a1938b93","symbols_score_info":{"HBMX":1.5,"MUZ":0.6,"RAMZ":0.6,"MUD":0.6,"02142":0.9,"COPP":0.6,"HBM":0.9,"MUG":0.6,"MUYY":0.6,"DRMP":1.5,"DISK":1.5,"DRAL":0.6,"RAM":0.6,"MULL":1.5,"DRAM":1.5,"MUU":0.6,"DRMY":1.5,"MIC":0.6},"content_text":"HBM Holdings (SEHK:2142) is in focus after China’s drug regulator approved batoclimab, a subcutaneous biologic for generalized myasthenia gravis, backed by a pivotal Phase 3 study showing clinically meaningful patient improvements. HBM Holdings has had a choppy year in the market, with the 30-day share price return down 25.96% and the year-to-date share price return down 15.23%. However, the 3-year total shareholder return is very large at around 7x, so momentum has cooled recently even as long term holders still sit on substantial gains. Scan beyond HBM Holdings and surface other antibody and biotech players with potential catalysts using our curated 613 high quality undiscovered gems in the same high-risk, high-reward corner of the market. HBM Holdings now trades well below its recent highs after a sharp pullback, coming immediately after a major drug approval. Do you lean into the weakness or wait for the valuation section to highlight a clearer entry window? AdvertisementMost Popular Narrative: 57% Undervalued HBM Holdings closed at HK$10.24 while the most followed narrative anchors fair value around HK$24.02. The current pullback sits well below that framework and shifts attention to how durable the pipeline and earnings story really is.  Ongoing build out of Harbour BioMed’s platform based model, with three defined growth engines in assets, technology and partnerships, points to additional collaboration and out licensing income that could support revenue and earnings.  See why 1 investors see HBM Holdings as 57% undervalued. Result: Fair Value of HK$24.02 (UNDERVALUED) Still, this hinges on HBM Holdings keeping key respiratory and oncology programs on track, as well as collaboration or licensing deals arriving in a timely way. Find out about the key risks to this HBM Holdings narrative. Next Steps This mix of enthusiasm and caution around HBM Holdings leaves the verdict open. Move quickly, test the assumptions against the numbers, and then weigh both sides through 4 key rewards and 1 important warning sign. Looking for more HBM Holdings investment ideas? If you want to pressure test your view on HBM Holdings, branch out into similar opportunities and compare risk, quality, and income profiles side by side.  Chase asymmetrical upside by scanning a focused list of high potential small caps through 122 elite penny stocks with strong financials. Zero in on quality at a discount by using the 193 high quality undervalued stocks to spot businesses where fundamentals and price are out of sync. Build a more resilient income stream by anchoring your research around the 225 dividend fortresses and see which payouts might complement higher risk biotech exposure.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HBM Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2678918099","isCrawlerRequest":true}